Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar:13:168-173.
doi: 10.1016/j.cobme.2020.03.005. Epub 2020 Apr 1.

Bioengineered Tumor Organoids

Anthony Dominijanni  1 , Andrea Mazzocchi  1 , Ethan Shelkey  1 , Steven Forsythe  1 , Mahesh Devarsetty  1 , Shay Soker  1
Affiliations

Bioengineered Tumor Organoids

Anthony Dominijanni et al. Curr Opin Biomed Eng. 2020 Mar.

Abstract

Recent advances in biofabrication technologies, such as cell culture systems, and biomaterials have led to the development of three-dimensional (3D) cell culture platforms, such as tumor organoids. Tumor organoids are more physiologically accurate to the in vivo system, which they are intended to model, compared with traditional 2D cancer cell culture systems. Tumor organoids can mimic pathological and physical characteristics of tumors as well as maintain genetic stability of the cancer cells. Furthermore tumor organoids have advantage over animal models, being made from human cells and easily controlled in the laboratory to attain the desired tissue characteristics. In this section, we describe general tumor organoid technologies, the importance of the tumor microenvironment (TME) in model culture systems, and the use of tumor organoids in drug development and precision medicine. Organoid technologies continue to develop rapidly for applications in academic, clinical, and pharmaceutical settings.

Keywords: 3D Cell Culture; Cancer Modelling; Extracellular Matrix; Tumor Microenvironment; Tumor Organoids.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Three-dimensional organoid techniques that are used in cancer research. These bioengineered 3D organoid platforms better recapitulate structure and cellular heterogeneity of in vivo tumor tissue and are therefore more appropriate to model the desired tumor type.
See this image and copyright information in PMC

References

    1. Vlachogiannis G, et al., Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science, 2018. 359(6378): p. 920–926.

      ** This recent review paper compares the responses to chemotheraputic agents Ex vivo in organoids and PDO-based orthotopic mouse tumor xenograph models with the responses of the patients in clinical trials and suggest that PDOs can recapiculate patient responses and could be implemented in personalized medicine.

    1. Weeber F, et al., Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases. Proc Natl Acad Sci U S A, 2015. 112(43): p. 13308–11. - PMC - PubMed
    1. Mitra A, Mishra L, and Li S, Technologies for deriving primary tumor cells for use in personalized cancer therapy. Trends Biotechnol, 2013. 31(6): p. 347–54. - PMC - PubMed
    1. Forsythe S, Pu T, and Skardal A, Using organoid models to predict chemotherapy efficacy: the future of precision oncology? Expert Review of Precision Medicine and Drug Development, 2019. 4(6): p. 317–336.
    1. Balkwill FR, Capasso M, and Hagemann T, The tumor microenvironment at a glance. J Cell Sci, 2012. 125(Pt 23): p. 5591–6. - PubMed

LinkOut - more resources